866-997-4948(US-Canada Toll Free)

P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 63 Pages

P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2016

Summary

Global Markets Directs, P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2016, provides in depth analysis on P2X Purinoceptor 3 (P2RX3) targeted pipeline therapeutics.

The report provides comprehensive information on the P2X Purinoceptor 3 (P2RX3) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for P2X Purinoceptor 3 (P2RX3)
- The report reviews P2X Purinoceptor 3 (P2RX3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics and enlists all their major and minor projects
- The report assesses P2X Purinoceptor 3 (P2RX3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to P2X Purinoceptor 3 (P2RX3) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for P2X Purinoceptor 3 (P2RX3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding P2X Purinoceptor 3 (P2RX3) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
P2X Purinoceptor 3 (P2RX3) Overview 7
Therapeutics Development 8
P2X Purinoceptor 3 (P2RX3) - Products under Development by Stage of Development 8
P2X Purinoceptor 3 (P2RX3) - Products under Development by Therapy Area 9
P2X Purinoceptor 3 (P2RX3) - Products under Development by Indication 10
P2X Purinoceptor 3 (P2RX3) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
P2X Purinoceptor 3 (P2RX3) - Products under Development by Companies 14
P2X Purinoceptor 3 (P2RX3) - Products under Development by Universities/Institutes 16
P2X Purinoceptor 3 (P2RX3) - Therapeutics Assessment 18
Assessment by Monotherapy/Combination Products 18
Assessment by Mechanism of Action 19
Assessment by Route of Administration 20
Assessment by Molecule Type 21
P2X Purinoceptor 3 (P2RX3) - Companies Involved in Therapeutics Development 23
Afferent Pharmaceuticals, Inc. 23
Asana BioSciences, LLC 24
Bayer AG 25
Integral Molecular, Inc. 26
Neurim Pharmaceuticals Ltd 27
Pfizer Inc. 28
Shionogi & Co., Ltd. 29
P2X Purinoceptor 3 (P2RX3) - Drug Profiles 30
AF-130 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
AF-219 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
ASN-009 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Drug to Antagonize P2X3 for Endometriosis - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Monoclonal Antibodies to Antagonize P2X3 Receptor for Pain - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Monoclonal Antibody to Antagonize P2X2 and P2X3 for Visceral Pain - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
NEO-5937 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
OSX-300 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
OSX-300 Backups - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
piromelatine - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Small Molecule to Antagonize P2X3 Receptor for Neuropathic Pain - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
P2X Purinoceptor 3 (P2RX3) - Dormant Projects 45
P2X Purinoceptor 3 (P2RX3) - Discontinued Products 47
P2X Purinoceptor 3 (P2RX3) - Featured News & Press Releases 48
Sep 28, 2016: Neurim Pharmaceuticals Announces First Patients Enrollments in ReCOGNITION - Phase II Clinical Trial of Piromelatine for Mild Alzheimers Disease 48
Sep 05, 2016: Hypertension: releasing the pressure at its source 48
May 18, 2016: Afferent Pharmaceuticals Reports Cardiovascular Research Showing P2X3 Antagonism Successfully Reduces Hypertension By Restoring Autonomic Nervous Balance at the 2016 American Thoracic Society Conference 50
May 16, 2016: Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference 51
Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Chronic Cough Clinical Data at the Upcoming American Thoracic Society 2016 International Conference 53
Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Hypertension Research at the Upcoming American Thoracic Society 2016 International Conference 54
Dec 08, 2015: Afferent Pharmaceuticals Advances Novel Molecule, AF-130, to Phase 1 Clinical Trial 54
Nov 11, 2015: Afferent Pharmaceuticals Announces Phase 2 Clinical Trial with AF-219 in Cough in Idiopathic Pulmonary Fibrosis (IPF) Patients 55
Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial 55
Feb 26, 2015: Afferent Clinical Data for Lead Candidate, AF-219, Demonstrate Improvements in Pain and Urinary Urgency in Interstitial Cystitis / Bladder Pain Syndrome 56
Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet 57
Sep 09, 2013: Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Companys Lead P2X3 Antagonist, AF-219 58
Feb 18, 2013: Neurim Pharma Announces Positive Phase II Clinical Trial Results Of Piromelatine For Treatment Of Insomnia 59
Jul 24, 2011: Neurim Announces Positive Results From Phase I And Phase Ib Clinical Trials With Neu-P11 60
Aug 25, 2010: Afferent Reports Data Supporting Potential Utility Of P2X3 Antagonists In Lowering Bladder Reflexes 61
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 62
Disclaimer 63

List of Tables
Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Products under Development by Companies, H2 2016 15
Number of Products under Investigation by Universities/Institutes, H2 2016 16
Products under Investigation by Universities/Institutes, H2 2016 17
Assessment by Monotherapy/Combination Products, H2 2016 18
Number of Products by Stage and Mechanism of Action, H2 2016 19
Number of Products by Stage and Route of Administration, H2 2016 20
Number of Products by Stage and Molecule Type, H2 2016 22
Pipeline by Afferent Pharmaceuticals, Inc., H2 2016 23
Pipeline by Asana BioSciences, LLC, H2 2016 24
Pipeline by Bayer AG, H2 2016 25
Pipeline by Integral Molecular, Inc., H2 2016 26
Pipeline by Neurim Pharmaceuticals Ltd, H2 2016 27
Pipeline by Pfizer Inc., H2 2016 28
Pipeline by Shionogi & Co., Ltd., H2 2016 29
Dormant Projects, H2 2016 45
Dormant Projects (Contd..1), H2 2016 46
Discontinued Products, H2 2016 47

List of Figures
Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Top 10 Indication, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 13
Assessment by Monotherapy/Combination Products, H2 2016 18
Number of Products by Stage and Mechanism of Actions, H2 2016 19
Number of Products by Stage and Routes of Administration, H2 2016 20
Number of Products by Molecule Types, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 21

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *